Quercetin As An Inhibitor Of Snake Venom Secretory Phospholipase A2

As polyphenolic compounds isolated from plants extracts, flavonoids have been applied to various pharmaceutical uses in recent decades due to their anti-inflammatory, cancer preventive, and cardiovascular protective activities. In this study, we evaluated the effects of the flavonoid quercetin on Crotalus durissus terrificus secretory phospholipase A2 (sPLA2), an important protein involved in the release of arachidonic acid from phospholipid membranes. The protein was chemically modified by treatment with quercetin, which resulted in modifications in the secondary structure as evidenced through circular dichroism. In addition, quercetin was able to inhibit the enzymatic activity and some pharmacological activities of sPLA2, including its antibacterial activity, its ability to induce platelet aggregation, and its myotoxicity by approximately 40%, but was not able to reduce the inflammatory and neurotoxic activities of sPLA2. These results suggest the existence of two pharmacological sites in the protein, one that is correlated with the enzymatic site and another that is distinct from it. We also performed molecular docking to better understand the possible interactions between quercetin and sPLA2. Our docking data showed the existence of hydrogen-bonded, polar interactions and hydrophobic interactions, suggesting that other flavonoids with similar structures could bind to sPLA2. Further research is warranted to investigate the potential use of flavonoids as sPLA2 inhibitors. © 2010 Elsevier Ireland Ltd. All rights reserved.18901/02/15916Kini, R., Excitement ahead: Structure, function and mechanism of snake venom phospholipase A2 enzymes (2003) Toxicon, 42 (8), pp. 827-840Nevalainen, T., Graham, G., Scott, K., Antibacterial actions of secreted phospholipases A2. Review (2008) Biochim. Biophys. Acta, 1781 (12), pp. 1-9Burke, J., Dennis, E., Phospholipase A2 biochemistry (2009) Cardiovasc. Drugs Ther., 23 (1), pp. 49-59Evangelista, J., Martins, A., Nascimento, N., Sousa, C., Alves, R., Toyama, D., Toyama, M., Monteiro, H., Renal and vascular effects of the natriuretic peptide isolated from Crotalus durissus cascavella venom (2008) Toxicon, 52 (7), pp. 737-744Soares, A., Giglio, J., Chemical modifications of phospholipases A2 from snake venoms: Effects on catalytic and pharmacological properties (2003) Toxicon, 42 (8), pp. 855-868Kini, R., Chan, Y., Accelerated evolution and molecular surface of venom phospholipase A2 enzymes (1999) J. Mol. Evol., 48 (2), pp. 125-132Chakraborti, S., Phospholipase A(2) isoforms: A perspective (2003) Cell Signal., 15 (7), pp. 637-665Lättig, J., Böhl, M., Fischer, P., Tischer, S., Tietböhl, C., Menschikowski, M., Gutzeit, H., Pisabarro, M., Mechanism of inhibition of human secretory phospholipase A2 by flavonoids: Rationale for lead design (2007) J. Comput. Aided Mol. Des., 21 (8), pp. 473-483Di Carlo, G., Mascolo, N., Izzo, A., Capasso, F., Flavonoids: Old and new aspects of a class of natural therapeutic drugs (1999) Life Sci., 65 (4), pp. 337-353Gil, B., Sanz, M., Terencio, M., Gunasegaran, R., Paya, M., Alcaraz, M., Morelloflavone, a novel biflavonoid inhibitor of human secretory phospholipase A(2) with anti-inflammatory activity (1997) Biochem. Pharmacol., 53, p. 733Lindahl, M., Tagesson, C., Flavonoids as phospholipase A2 inhibitors: Importance of their structure for selective inhibition of group II phospholipase A2 (1997) Inflammation, 21 (3), pp. 347-356Iglesias, C., Aparicio, R., Rodrigues-Simioni, L., Camargo, E., Antunes, E., Marangoni, S., De Oliveira Toyama, D., Toyama, M., Effects of morin on snake venom phospholipase A2 (PLA2) (2005) Toxicon, 46 (7), pp. 751-758Lindahl, M., Tagesson, C., Selective inhibition of group II phospholipase A2 by quercetin (1993) Inflammation, 17 (5), pp. 573-582Toyama, M.H., De Oliveira, D.G., Beriam, L.O.S., Novello, J.C., Rodrigues-Simioni, L., Marangoni, S., Structural, enzymatic and biological properties of new PLA2 isoform from Crotalus durissus terrificus venom (2003) Toxicon, 41 (8), pp. 1033-1038. , DOI 10.1016/S0041-0101(03)00085-0Zhao, H., Tang, L., Wang, X., Zhou, Y., Lin, Z., Structure of a snake venom phospholipase A2 modified by p-bromo-phenacyl-bromide (1998) Toxicon, 36 (6), pp. 875-886Laemmli, U., Cleavage of structural proteins during the assembly of the head of bacteriophage T4 (1970) Nature, 227 (5259), pp. 680-685Wen-Hwa, L., Toyama, M.H., Soares, A.M., Giglio, J.R., Marangoni, S., Polikarpov, I., Crystallization and preliminary X-ray diffraction studies of piratoxin III, a D-49 phospholipase A2 from the venom of Bothrops pirajai (1999) Acta Crystallographica Section D: Biological Crystallography, 55 (6), pp. 1229-1230. , DOI 10.1107/S0907444999004576Santi-Gadelha, T., Rocha, B., Oliveira, C., Aragão, K., Marinho, E., Gadelha, C., Toyama, M., Cavada, B., Purification of a PHA-like chitin-binding protein from Acacia farnesiana seeds: A time-dependent oligomerization protein (2008) Appl. Biochem. Biotechnol., 150 (1), pp. 97-111Toyama, M., Toyama, D.O., Passero, L., Laurenti, M., Corbett, C., Tomokane, T., Fonseca, F., Fonteles, M., Isolation of a new l-amino acid oxidase from Crotalus durissus cascavella venom (2006) Toxicon, 47 (1), pp. 47-57Ginsborg, B., Warriner, J., The isolated chick biventer cervicis nerve-muscle preparation (1960) Br. J. Pharmacol. Chemother., 15, pp. 410-411Dewar, M.J.S., Zoebisch, E.G., Healy, E.F., Stewart, J.J.P., Development and use of quantum mechanical molecular models. 76. AM1: A new general purpose quantum mechanical molecular model (1985) J. Am. Chem. Soc., 107 (13), p. 8Jones, G., Willett, P., Glen, R., Leach, A., Taylor, R., Development and validation of a genetic algorithm for flexible docking (1997) J. Mol. Biol., 267 (3), pp. 727-748Verheij, H., Volwerk, J., Jansen, E., Puyk, W., Dijkstra, B., Drenth, J., De Haas, G., Methylation of histidine-48 in pancreatic phospholipase A2. Role of histidine and calcium ion in the catalytic mechanism (1980) Biochemistry, 19 (4), pp. 743-750Scott, D., Sigler, P., Structure and catalytic mechanism of secretory phospholipases A2 (1994) Adv. Protein Chem., 45, pp. 53-88Gil, B., Sanz, M., Terencio, M., Ferrándiz, M., Bustos, G., Payá, M., Gunasegaran, R., Alcaraz, M., Effects of flavonoids on Naja naja and human recombinant synovial phospholipases A2 and inflammatory responses in mice (1994) Life Sci., 54 (20), pp. 333-338Fonseca, F., Antunes, E., Morganti, R., Monteiro, H., Martins, A., Toyama, D., Marangoni, S., Toyama, M., Characterization of a new platelet aggregating factor from crotoxin Crotalus durissus cascavella venom (2006) Protein J., 25 (3), pp. 183-192Soares, A., Mancin, A., Cecchini, A., Arantes, E., Frana, S., Gutiérrez, J., Giglio, J., Effects of chemical modifications of crotoxin B, the phospholipase A(2) subunit of crotoxin from Crotalus durissus terrificus snake venom, on its enzymatic and pharmacological activities (2001) Int. J. Biochem. Cell Biol., 33 (9), pp. 877-888Diz Filho, E., Marangoni, S., Toyama, D., Fagundes, F., Oliveira, S., Fonseca, F., Calgarotto, A., Toyama, M., Enzymatic and structural characterization of new PLA2 isoform isolated from white venom of Crotalus durissus ruruima (2009) Toxicon, 53 (1), pp. 104-114Buckland, A., Wilton, D., The antibacterial properties of secreted phospholipases A(2) (2000) Biochim. Biophys. Acta, 1488 (12), pp. 71-82Kim, H., Pham, H., Ziboh, V., Flavonoids differentially inhibit guinea pig epidermal cytosolic phospholipase A2 (2001) Prostaglandins Leukot. Essent. Fatty Acids, 65 (56), pp. 281-286Toyama, D., Marangoni, S., Diz-Filho, E., Oliveira, S., Toyama, M., Effect of umbelliferone (7-hydroxycoumarin, 7-HOC) on the enzymatic, edematogenic and necrotic activities of secretory phospholipase A2 (sPLA2) isolated from Crotalus durissus collilineatus venom (2009) Toxicon, 53 (4), pp. 417-426Ohno, M., Chijiwa, T., Oda-Ueda, N., Ogawa, T., Hattori, S., Molecular evolution of myotoxic phospholipases A2 from snake venom (2003) Toxicon, 42 (8), pp. 841-854Valentin, E., Lambeau, G., Increasing molecular diversity of secreted phospholipases A(2) and their receptors and binding proteins (2000) Biochim. Biophys. Acta, 1488 (12), pp. 59-70Halperin, I., Ma, B., Wolfson, H., Nussinov, R., Principles of docking: An overview of search algorithms and a guide to scoring functions (2002) Proteins, 47 (4), pp. 409-44

Sulfated polysaccharide extracted of the green algae Caulerpa racemosa increase the enzymatic activity and paw edema induced by sPLA2 from Crotalus durissus terrificus venom

Sulfated polysaccharides derived from seaweed have shown great potential for use in the development of new drugs. In this study, we observed that a low-molecular-weight sulfated polysaccharide from Caulerpa racemosa, termed CrSP, could interact with secretory phospholipase A2 (sPLA2) isolated from Crotalus durissus terrificus venom. When native sPLA2 (14 kDa) was incubated with CrSP, they formed a molecular complex (sPLA2:CrSP) with a molecular mass of 32 kDa, approximately. Size exclusion chromatography experiments suggested that CrSP formed a stable complex with sPLA2. We belived that sPLA2 and SPCr are involved an ionic interaction between negatively charged CrSP and the positively charged basic amino acid residues of sPLA2, because this interaction induced significant changes in sPLA2 enzymatic and pharmacological activities. CrSP caused a significant increase in sPLA2 enzymatic and bactericidal activity and increased its edematogenic effect. A pharmacological assay showed that the myotoxic activity of sPLA2:CrSP is unrelated to its enzymatic activity and that sPLA2:CrSP may have a practical application as a natural antibacterial agent for use in humans and commercially raised animals

Purification And Amino Acid Sequence Of Mp-iii 4r D49 Phospholipase A2 From Bothrops Pirajai Snake Venom, A Toxin With Moderate Pla2 And Anticoagulant Activities And High Myotoxic Activity.

MP-III 4R PLA2 was purified from the venom of Bothrops pirajai venom (Bahia's jararacussu) after three chromatographic steps which started with RP-HPLC. The complete amino acid sequence of MP-III 4R PLA2 from Bothrops pirajai was determined by amino acid sequencing of reduced and carboxymethylated MP-III 4R and the isolated peptides from clostripain and protease V8 digestion. MP-III 4R is a D49 PLA2 with 121 amino acid residues and has a molecular weight estimated at 13,800 Da, with 14 half-cysteines. This protein showed moderate PLA2 and anticoagulant activity. This PLA2 does not have a high degree of homology with other bothropic PLA2-like myotoxins (approximately 75%) and nonbothropic myotoxins (approximately 60%). MP-III 4R is a new PLA2, which was isolated using exclusively analytical and preparative HPLC methods. Based on the N-terminal sequence and biological activities, MP-III 4R was identified as similar to piratoxin-III (PrTX-III), which was isolated by conventional chromatography based on molecular exclusion ion exchange chromatography. Clinical manifestations indicate that at the site of toxin injection, there may be pain of variable intensity, because animals continue to lick the limb. No clinical sign indicating general toxicity was noticed. Myotoxicity was observed in gastrocnemius muscle cells after exposure to MP-III 4R, with a high frequency (70%) of affected muscle fibers.18371-